Aquestive Therapeutics Stock Fundamentals
| AQST Stock | USD 3.08 0.02 0.65% |
Aquestive Therapeutics fundamentals help investors to digest information that contributes to Aquestive Therapeutics' financial success or failures. It also enables traders to predict the movement of Aquestive Stock. The fundamental analysis module provides a way to measure Aquestive Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aquestive Therapeutics stock.
At this time, Aquestive Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 92.3 M in 2025, whereas Operating Income is likely to drop (14.3 M) in 2025. Aquestive | Select Account or Indicator |
Aquestive Therapeutics Company Shares Outstanding Analysis
Aquestive Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Aquestive Therapeutics Shares Outstanding | 91.18 M |
Most of Aquestive Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aquestive Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Aquestive Shares Outstanding Historical Pattern
Today, most investors in Aquestive Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Aquestive Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Aquestive Therapeutics shares outstanding as a starting point in their analysis.
Aquestive Therapeutics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Aquestive Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Aquestive Therapeutics has 91.18 M of shares currently outstending. This is 49.5% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The shares outstanding for all United States stocks is 84.05% higher than that of the company.
Aquestive Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aquestive Therapeutics's current stock value. Our valuation model uses many indicators to compare Aquestive Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aquestive Therapeutics competition to find correlations between indicators driving Aquestive Therapeutics's intrinsic value. More Info.Aquestive Therapeutics is rated below average in return on asset category among its peers. It is rated below average in profit margin category among its peers . At this time, Aquestive Therapeutics' Net Loss is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Aquestive Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Aquestive Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aquestive Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aquestive Therapeutics could also be used in its relative valuation, which is a method of valuing Aquestive Therapeutics by comparing valuation metrics of similar companies.Aquestive Therapeutics is currently under evaluation in shares outstanding category among its peers.
Aquestive Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Aquestive Therapeutics from analyzing Aquestive Therapeutics' financial statements. These drivers represent accounts that assess Aquestive Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aquestive Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 180.0M | 148.1M | 44.0M | 123.7M | 142.3M | 141.9M | |
| Enterprise Value | 188.7M | 176.5M | 72.8M | 133.2M | 153.2M | 155.3M |
Aquestive Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aquestive Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aquestive Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Aquestive Fundamentals
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.60) % | ||||
| Operating Margin | (0.61) % | ||||
| Current Valuation | 241.63 M | ||||
| Shares Outstanding | 91.18 M | ||||
| Shares Owned By Insiders | 5.00 % | ||||
| Shares Owned By Institutions | 56.44 % | ||||
| Number Of Shares Shorted | 11.79 M | ||||
| Price To Earning | (1.90) X | ||||
| Price To Sales | 4.77 X | ||||
| Revenue | 50.58 M | ||||
| Gross Profit | 40.87 M | ||||
| EBITDA | 1.18 M | ||||
| Net Income | (7.87 M) | ||||
| Cash And Equivalents | 17.7 M | ||||
| Cash Per Share | 0.33 X | ||||
| Total Debt | 33.32 M | ||||
| Debt To Equity | 468.20 % | ||||
| Current Ratio | 1.47 X | ||||
| Book Value Per Share | (0.50) X | ||||
| Cash Flow From Operations | (6.38 M) | ||||
| Short Ratio | 7.25 X | ||||
| Earnings Per Share | (0.45) X | ||||
| Target Price | 10.83 | ||||
| Number Of Employees | 135 | ||||
| Beta | 2.82 | ||||
| Market Capitalization | 280.83 M | ||||
| Total Asset | 57.42 M | ||||
| Retained Earnings | (319.08 M) | ||||
| Working Capital | 22.66 M | ||||
| Current Asset | 38.38 M | ||||
| Current Liabilities | 17.95 M | ||||
| Net Asset | 57.42 M |
About Aquestive Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aquestive Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aquestive Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aquestive Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.8 M | 1.1 M | |
| Total Revenue | 58.2 M | 48.2 M | |
| Cost Of Revenue | 24 M | 16.3 M | |
| Stock Based Compensation To Revenue | 0.06 | 0.06 | |
| Sales General And Administrative To Revenue | 0.96 | 0.50 | |
| Research And Ddevelopement To Revenue | 0.30 | 0.37 | |
| Capex To Revenue | 0.02 | 0.02 | |
| Revenue Per Share | 0.95 | 0.90 | |
| Ebit Per Revenue | (0.34) | (0.36) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.